 HIV Seropositivity
"HIV Seropositivity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).
| Descriptor ID |
D006679
|
| MeSH Number(s) |
C02.782.815.616.400.500 C02.800.801.400.500 C20.673.480.500
|
| Concept/Terms |
HIV Seropositivity- HIV Seropositivity
- HIV Seropositivities
- Seropositivities, HIV
- Seropositivity, HIV
- AIDS Seropositivity
- AIDS Seropositivities
- Seropositivities, AIDS
- Seropositivity, AIDS
- Anti-HIV Positivity
- Anti HIV Positivity
- Anti-HIV Positivities
- Positivities, Anti-HIV
- Positivity, Anti-HIV
- HTLV-III Seropositivity
- HTLV III Seropositivity
- HTLV-III Seropositivities
- Seropositivities, HTLV-III
- Seropositivity, HTLV-III
- HIV Seroconversion
- HIV Seroconversions
- Seroconversion, HIV
- Seroconversions, HIV
- HTLV-III Seroconversion
- HTLV III Seroconversion
- HTLV-III Seroconversions
- Seroconversion, HTLV-III
- Seroconversions, HTLV-III
- AIDS Seroconversion
- AIDS Seroconversions
- Seroconversion, AIDS
- Seroconversions, AIDS
- HIV Antibody Positivity
- Antibody Positivities, HIV
- Antibody Positivity, HIV
- HIV Antibody Positivities
- Positivities, HIV Antibody
- Positivity, HIV Antibody
|
Below are MeSH descriptors whose meaning is more general than "HIV Seropositivity".
Below are MeSH descriptors whose meaning is more specific than "HIV Seropositivity".
This graph shows the total number of publications written about "HIV Seropositivity" by people in this website by year, and whether "HIV Seropositivity" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 0 | 2 | | 1998 | 2 | 3 | 5 | | 1999 | 2 | 1 | 3 | | 2001 | 2 | 1 | 3 | | 2002 | 1 | 1 | 2 | | 2003 | 0 | 2 | 2 | | 2005 | 2 | 3 | 5 | | 2006 | 0 | 2 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 0 | 1 | 1 | | 2009 | 3 | 2 | 5 | | 2010 | 1 | 1 | 2 | | 2011 | 5 | 2 | 7 | | 2012 | 5 | 2 | 7 | | 2013 | 4 | 0 | 4 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 7 | 9 | | 2019 | 1 | 2 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 1 | 1 | 2 | | 2022 | 5 | 0 | 5 | | 2023 | 6 | 0 | 6 | | 2024 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Seropositivity" by people in Profiles.
-
Debroy P, Barrett BW, Erlandson KM, Budoff M, Brown TT, Price JC, Post WS, Stosor V, Skavarca C, D'Souza G, Lake JE. Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus. J Acquir Immune Defic Syndr. 2024 Oct 01; 97(2):165-171.
-
Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study. Lancet HIV. 2024 Apr; 11(4):e222-e232.
-
Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Crain CR, Traunbauer AK, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Dorazio D, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Sieg S, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZ. Viral and host mediators of non-suppressible HIV-1 viremia. Nat Med. 2023 Dec; 29(12):3212-3223.
-
Sabourin KR, Ogolla S, Reyes GS, Daud I, Jackson CL, Labo N, Miley W, Whitby D, Lamb MM, Rochford R, Dent A. Effects of Maternal HIV Infection on Early Kaposi Sarcoma-Associated Herpesvirus Seroconversion in a Kenyan Mother-Infant Cohort. J Infect Dis. 2023 11 11; 228(10):1357-1366.
-
Singh Y, Castillo-Mancilla J, Madimabe R, Jennings L, Ferraris CM, Robbins RN, Anderson PL, Remien RH, Orrell C. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa. AIDS Res Ther. 2023 09 14; 20(1):67.
-
Sanz M, Weideman AMK, Ward AR, Clohosey ML, Garcia-Recio S, Selitsky SR, Mann BT, Iannone MA, Whitworth CP, Chitrakar A, Garrido C, Kirchherr J, Coffey AR, Tsai YH, Samir S, Xu Y, Copertino D, Bosque A, Jones BR, Parker JS, Hudgens MG, Goonetilleke N, Soriano-Sarabia N. Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1. Front Immunol. 2023; 14:1219250.
-
Wirtz AL, Humes E, Althoff KN, Poteat TC, Radix A, Mayer KH, Schneider JS, Haw JS, Wawrzyniak AJ, Cannon CM, Stevenson M, Cooney EE, Adams D, Case J, Beyrer C, Laeyendecker O, Rodriguez AE, Reisner SL. HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study. Lancet HIV. 2023 05; 10(5):e308-e319.
-
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 02 01; 92(2):153-161.
-
Sertznig H, Roesmann F, Wilhelm A, Heininger D, Bleekmann B, Elsner C, Santiago M, Schuhenn J, Karakoese Z, Benatzy Y, Snodgrass R, Esser S, Sutter K, Dittmer U, Widera M. SRSF1 acts as an IFN-I-regulated cellular dependency factor decisively affecting HIV-1 post-integration steps. Front Immunol. 2022; 13:935800.
-
Ollerton MT, Folkvord JM, La Mantia A, Parry DA, Meditz AL, McCarter MD, D'Aquila RT, Connick E. Follicular regulatory T cells eliminate HIV-1-infected follicular helper T cells in an IL-2 concentration dependent manner. Front Immunol. 2022; 13:878273.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|